Opendata, web and dolomites

RSVTriVax SIGNED

Development of a trivalent epitope-focused RSV vaccine to boost pre-existing immunity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RSVTriVax project word cloud

Explore the words cloud of the RSVTriVax project. It provides you a very rough idea of what is the project "RSVTriVax" about.

compelling    functional    animal    profile    thereby    populations    protect    abs    societal    attributed    respiratory    carries    infection    preliminary    organization    epitopes    women    suggesting    syncytial    cocktail    viral    edge    primary    cohort    immunogens    strongest    safety    children    competitive    induction    emerge    120    young    globally    public    mimicking    million    promise    iuml    scenario    competitor    intensive    prevent    global    pregnant    yield    clinically    candidate    burdens    health    virus    pathogen    mechanisms    infections    antibodies    boost    deaths    molecules    model    protective    rsv    boosting    cutting    tools    natural    33    good    stable    sophisticated    ve    potent    causes    consolidate    annually    commercial    vaccine    epitope    na    world    primates    alternative    elderly    manufacturing    eliciting    human    approved    elicited    episodes    deemed    trivax    exquisite    financial    mostly    formulation    showed    immune    molecular    decades    neutralizing    close    candidates    superior    subdominant    neutralization    protection    infants   

Project "RSVTriVax" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 150˙000.00

Map

 Project objective

The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most affected populations are pre-term infants, young children and the elderly. Several decades of intensive research are yet to yield a clinically approved vaccine. This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective antibodies (Abs). Using cutting-edge molecular design tools, we developed a novel vaccine candidate (TriVax) to focus immune responses in such key neutralization epitopes. TriVax is a cocktail composed of three epitope-focused immunogens mimicking three distinct neutralization epitopes targeted by potent neutralizing Abs. Our primary target populations are pregnant women (protection of pre-term infants) and elderly, where the challenge is to boost subdominant, neutralizing Abs elicited during previous natural infections. Recently, we showed that epitope-focused immunogens are exquisite at boosting subdominant functional Abs, and in this scenario, superior to the strongest competitor vaccine candidates. In a preliminary study in Non-Human Primates, TriVax showed great promise by eliciting robust neutralization on an RSV naïve cohort, suggesting a good safety profile and the potential to emerge as a competitive alternative for vaccine development. For manufacturing, epitope-focused immunogens are simple and stable molecules that can be produced at low cost. Overall, we propose a viable vaccine formulation to protect against an important pathogen which carries large financial burdens on public health systems. Thus, our proposal has an important societal and financial impact, and will provide compelling evidence for Trivax to boost neutralizing Abs in a close-to-human animal model, thereby taking an essential step to consolidate the commercial potential of our vaccine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RSVTRIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RSVTRIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

TRUST (2018)

Truth and Semantics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More